A 2025 report in Case Reports in Oncology documented an 83-year-old patient with metastatic breast cancer who achieved complete radiologic remission while self-administering fenbendazole. During this time, the patient was also receiving fulvestrant, a standard estrogen receptor–blocking hormone therapy, and targeted radiation for spinal lesions. By April 2022, a PET-CT scan confirmed no abnormal metabolic activity, marking a significant milestone in her health journey. The patient had originally